Skip to main content

Nervous System Diseases clinical trials at UC Health
4 in progress, 3 open to new patients

  • AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)

    open to eligible people ages 18–80

    The CENTAUR trial will be a 2:1 (active:placebo) randomized, double-blind, placebo-controlled Phase II trial to evaluate the safety and efficacy of AMX0035 for the treatment of ALS.

    at UC Irvine

  • Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects

    open to eligible people ages 18 years and up

    Glioblastoma (GBM) and gliosarcoma (GS) are the most common and aggressive forms of malignant brain tumor in adults and can be resistant to conventional therapies. The purpose of this Phase II study is to evaluate how well a recurrent glioblastoma or gliosarcoma tumor responds to one injection of DNX-2401, a genetically modified oncolytic adenovirus, when delivered directly into the tumor followed by the administration of intravenous pembrolizumab (an immune checkpoint inhibitor) given every 3 weeks for up to 2 years or until disease progression. Funding Source-FDA OOPD

    at UCLA

  • Safety and Efficacy Study of VY-AADC01 for Advanced Parkinson's Disease

    open to eligible people ages 40–75

    Safety and efficacy of AADC gene transfer in participants with Parkinson's disease.

    at UCSF

  • Phase 3 Extension Study of Ataluren (PTC124) in Patients With Nonsense Mutation Dystrophinopathy

    Sorry, in progress, not accepting new patients

    The main goal of this Phase 3 extension study is to obtain long term safety of ataluren in boys with nonsense mutation dystrophinopathy as determined by adverse events and laboratory abnormalities. The study will also assess changes in physical function, pulmonary function and other important clinical and laboratory measures.

    at UCLAUC Davis